Edison International (EIX) Q1 2025 Earnings Call April 29, 2025 09:22 PM ET Speaker0 Good afternoon, and welcome to the Edison International First Quarter twenty twenty five Financial Teleconference. My name is Michelle, and I will be your operator today. Today's call is being recorded. I would now like to turn the call over to Mr. Sam Ramraj, Vice President of Investor Relations. Mr. Ramraj, you may begin your conference. Speaker1 Thank you, Michelle, and welcome, everyone. Our speakers today are President ...

Ribbon Communications (RBBN) Q1 2025 Earnings Call April 29, 2025 09:19 PM ET Speaker0 Greetings, and welcome to the Ribbon Communications First Quarter twenty twenty five Financial Results Conference Call. At this time, all participants are in a listen only mode. A question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Joni Roberts, Chief Marketing Officer. Please go ahead. Speaker1 Good a ...

Rocky Brands (RCKY) Q1 2025 Earnings Call April 29, 2025 09:19 PM ET Speaker0 Ladies and gentlemen, greetings, and welcome to the Rocky Brands Inc. First Quarter Fiscal twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. A brief question and answer session will follow the formal presentation. As a reminder, this conference is being recorded. It is now my pleasure to introduce your host, Cody McAllister of ICR. Please go ahead. Speaker1 Thank you, and thanks ...

Financial Data and Key Metrics Changes - In Q1 2025, the company reported collaboration revenue of $13.8 million, a 21% increase from Q4 2024 [15][18] - R&D expenses were $22.8 million, reflecting a 68% decrease compared to Q1 2024, and a nearly 40% decrease from Q4 2024 [16][17] - The net loss for Q1 2025 was $62.2 million, down from a net loss of $95.8 million in Q4 2024 [18] Business Line Data and Key Metrics Changes - XERZUVEY was shipped to over 3,000 women with postpartum depression (PPD) in Q1 2025, representing a 22% increase from Q4 2024 [7][12] - The company generated $13.8 million in collaboration revenue for XERZUVEY, which is 50% of the net revenue reported by Biogen, marking a 21% increase from the previous quarter [15][18] - Over 70% of women prescribed XERZUVEY received it as their first new treatment for PPD [12][40] Market Data and Key Metrics Changes - The majority of prescriptions (almost 80%) in Q1 2025 came from OBGYNs, indicating a strong focus on peripartum care [12][26] - The total number of XERZUVEY writers increased by over 20% in Q1 2025 [12] Company Strategy and Development Direction - The company is focused on establishing XERZUVEY as the standard of care for women with PPD and is actively working to expand its reach [6][8] - A strategic alternatives process is ongoing to evaluate opportunities for maximizing shareholder value [6] - The company has recalibrated its R&D approach to prioritize neuropsychiatry and neurodevelopmental disorders, with a focus on SAGE-319 and the NMDA receptor NAM platform [9][10] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing commercialization of XERZUVEY and the potential for significant growth in 2025 [11][18] - The cash runway is expected to support operations until mid-2027, with plans to create shareholder value through focused R&D and commercialization efforts [18][108] Other Important Information - The company has seen a paradigm shift in how healthcare providers are screening, diagnosing, and treating PPD [7][8] - The sales force expansion is complete, and management anticipates continued quarter-over-quarter growth in demand and revenue [12][39] Q&A Session Summary Question: What kind of early pull through are you seeing from your Salesforce initiatives? - Management noted strong first-quarter growth of over 20% in demand and revenue, attributing this to the expanded sales force [25][26] Question: Could you provide some additional color on the pipeline and your upcoming catalysts? - Management expressed confidence in the recalibrated R&D approach and the pharmacology of their drugs, believing they will create significant shareholder value if successful [31][33] Question: What do you believe are the key factors for prescribers and patients deciding not to use XERZUVEY as their first-line treatment? - Management indicated that over 70% of women prescribed XERZUVEY are receiving it as their first treatment, suggesting minimal obstacles to frontline use [40][41] Question: Can you speak about the concentrations of the sales force in particular regions? - Management confirmed that the sales force expansion is complete and they expect continued growth in regions where the sales force has been expanded [39] Question: How should we think about the acceleration in growth in shipments as the quarters progress? - Management reiterated their expectation of quarter-over-quarter growth and noted that they are not providing forward-looking forecasts [56][57] Question: What is the current awareness of XERZUVEY among OBGYNs and the expecting mother community? - Management reported approximately 90% aided awareness among physicians treating PPD, which is considered remarkably high for a product at this stage [65][66] Question: Has anything changed regarding Biogen's commitment to the product? - Management stated that there has been no change in the partnership with Biogen, and both parties are excited about the product's impact [72] Question: What is the persistence of prescribers for XERZUVEY? - Management indicated that once a healthcare provider prescribes XERZUVEY, they tend to become repeat writers, with no significant drop-off observed [114]

AudioEye (AEYE) Q1 2025 Earnings Call April 29, 2025 09:12 PM ET Speaker0 Good afternoon, and welcome to AudioEye's First Quarter twenty twenty five Earnings Conference Call. Joining us for today's call are AudioEye's CEO, Mr. David Marotti and CFO, Ms. Kelly Georgievich. Following their remarks, we will open the call for questions from the company's publishing analysts. I would like to remind everyone that this call will be recorded and made available for replay via a link available in the Investor Relatio ...

Financial Data and Key Metrics Changes - Net revenue for Q1 2025 was $26.6 million, a decrease from $46.5 million in Q1 2024, primarily due to a temporary payment suspension from TRICARE and slowing order growth [20][21] - Gross profit in Q1 2025 was $18.2 million, representing 69% of revenue, compared to $37.2 million or 80% of revenue in Q1 2024 [20][21] - Net loss for Q1 2025 was $10.4 million, or $0.33 per share, compared to a net income of $10,000 in the previous year [21][22] Business Line Data and Key Metrics Changes - Device revenue was $11.9 million, while supplies revenue was $14.7 million in Q1 2025 [20] - Non-NexWave product order percentage increased to 34% in Q1 2025, up from an average of 30% in the previous year [13] Market Data and Key Metrics Changes - The company is experiencing a temporary payment suspension from TRICARE, which has affected revenue recognition [6][12] - The patient monitoring market is identified as a multibillion-dollar opportunity, with the company planning to enter with a superior product [19] Company Strategy and Development Direction - The company is restructuring to operate without TRICARE business in a worst-case scenario and is focusing on new revenue opportunities [9][10] - The company aims to generate revenue exceeding $800 million annually in the long term [25] - The launch of the Nico pulse oximeter is anticipated to significantly impact the patient monitoring market, with a focus on improving health equity [19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth prospects despite current challenges, emphasizing a commitment to high-quality service and technology [24][25] - The company expects to receive a response from TRICARE regarding the payment suspension within 40 days [24] Other Important Information - The company has reduced overall staff by approximately 15%, primarily in the corporate office, which is expected to result in annual savings of about $35 million [13] - The company maintains a strong balance sheet with $40 million in working capital and approximately $24 million in cash [22] Q&A Session Summary Question: Insights into TRICARE conversations and potential domino effects - Management indicated that the claims from TRICARE were vague and emphasized compliance with guidelines, stating there are no current issues with other payers [28][30][31] Question: Clarification on Q1 revenue miss and future guidance - The revenue miss was attributed to multiple factors, and management is waiting for clarity on TRICARE before providing full-year guidance [32][34][35] Question: Confirmation of TRICARE payments in Q1 and Q2 guidance - Management confirmed that Q1 revenue and guidance for Q2 do not include TRICARE payments, and they expect reimbursement for claims once the suspension is lifted [37][38] Question: Plans if TRICARE outcome is negative - The company plans to refocus its sales force to generate revenue from other areas if TRICARE payments are not restored [40][41] Question: Expected revenue from Nico post-approval - Management expects to launch Nico immediately upon FDA clearance, with revenue anticipated in 2026 [42]

Alexandria Real Estate Equities (ARE) Q1 2025 Earnings Call April 29, 2025 08:44 PM ET Speaker0 Good day, and welcome to the Alexandria Real Estate Equities First Quarter twenty twenty five Conference Call. All participants will be in the listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Paula Schwartz. Please go ahead. Speaker1 Thank you, and good afternoon, everyone. This conference call contains forward looking statements within the meaning of the ...

Financial Data and Key Metrics Changes - The company achieved a 17% year-on-year growth in on-demand GMV and recorded another quarter of record revenues, with a trailing twelve-month adjusted free cash flow expanding to $157 million [5][6] - Adjusted EBITDA outlook for the full year 2025 was raised to $460 million to $480 million from a previous range of $440 million to $470 million [6] Business Line Data and Key Metrics Changes - Monthly transacting users reached a record high, contributing to the overall revenue growth [5] - Delivery MTUs continued to grow sequentially, particularly with strong performance from Grab Mart [20][54] Market Data and Key Metrics Changes - The company noted no signs of consumer weakness despite macroeconomic uncertainties, with demand remaining strong in April [20][36] - The Indonesian market outperformed its closest competitor, with delivery MTUs growing sequentially [54] Company Strategy and Development Direction - The company aims to position itself as a countercyclical entity, focusing on reliability and affordability to drive user growth and retention [5][6] - New product initiatives, including AI-driven services, are expected to enhance operational performance without compromising margins [22][26] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in maintaining growth momentum despite potential macroeconomic headwinds, citing strong performance in Q1 and expectations for continued demand [6][36] - The company is closely monitoring the macro environment but remains optimistic about its ability to navigate challenges [33][39] Other Important Information - The company is focusing on enhancing its ecosystem through affordable products and viral initiatives to increase user engagement [26][41] - The FinTech segment is expected to see growth in lending to consumers, with a focus on prudent credit management [108][111] Q&A Session Summary Question: Changes in consumer behavior amid weakening macros - Management has not observed any signs of consumer weakness and expects a rebound in growth rates across mobility and deliveries in Q2 [20][21] Question: Confidence in higher EBITDA guidance - The company is confident due to strong Q1 performance, with demand remaining robust and cost optimization efforts in place [33][36] Question: Plans if demand softens - Management indicated they would monitor the situation closely and may consider promotions to stimulate demand if necessary [33] Question: Industry consolidation in delivery - The company believes there is still room for growth in the delivery segment despite ongoing consolidation in the industry [48][51] Question: Performance in Indonesia compared to competitors - The company outperformed its closest competitor in Indonesia, with strong growth in deliveries and a decline in direct marketing costs [54][55] Question: Thoughts on AV partnerships - The company is excited about the potential of autonomous vehicles and is actively exploring partnerships, though timelines for pilot deployments are not yet established [97][99] Question: Differences in FinTech models - The company focuses on supporting partners with credit underwriting advantages, which helps maintain stable NPLs [108][111] Question: Monetization of dine-out discovery - The company is enhancing dine-out discovery capabilities, which is expected to tap into a larger market and generate advertising revenue in the future [112][115]

Financial Data and Key Metrics Changes - Adjusted EBITDA reached a record high, marking a significant increase from 2023, with 19 of the 20 highest volume days recorded on Transco occurring this past winter [23] - The company returned over $2.3 billion in dividends to shareholders, maintaining a tradition of paying dividends every quarter for over fifty years [23] - The company achieved a 5% compound annual growth rate on dividends and an annualized total shareholder return compound annual growth rate of nearly 30% over the last five years [24] Business Line Data and Key Metrics Changes - The company placed six projects into service during the year and announced an additional six new projects, including expansions designed to support the conversion of electric power plants from coal to gas [25] - Twelve high-return transmission projects are currently in execution, which will add more than 3.25 billion cubic feet per day to the transmission systems [26] Market Data and Key Metrics Changes - There was an unprecedented surge in demand for long-term capacity on pipeline systems, driven by increasing natural gas demand from domestic power generation, LNG exports, and industrial reshoring [22] - The company operates more than 33,000 miles of pipeline, handling approximately one-third of the U.S. produced natural gas [20] Company Strategy and Development Direction - The company remains focused on natural gas infrastructure, which is seen as a critical component for supporting power grid reliability as more intermittent renewables are developed [22] - The company is modernizing facilities with high-efficiency compression and utilizing technology to enhance transparency in emissions profiles [27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the financial strength of the business, driven by a large portfolio of fully contracted, high-return growth projects over the next five years [21] - The company is committed to operating sustainably and has been recognized for its efforts in corporate sustainability [29] Other Important Information - The company has been named to the Dow Jones Sustainability North American Index for five consecutive years and holds the top score in the 2024 Corporate Sustainability Assessment in the North American oil and gas storage and transportation industry [29] Q&A Session Summary - No questions were submitted by shareholders during the meeting [33]

Financial Data and Key Metrics Changes - In Q1 2025, the company reported GAAP diluted EPS of $0.49 and adjusted diluted EPS of $0.50, reflecting a nearly 41% increase in net income compared to Q1 2024 [10][14] - Revenue for Q1 2025 was $167.6 million, a 12% increase from $149.4 million in Q1 2024, primarily due to rate increases in California and Connecticut [15][16] - GAAP net income was $16.6 million, a 41% increase year-over-year, while adjusted net income was $16.7 million, a 43% increase [15][16] Business Line Data and Key Metrics Changes - The company invested $70.8 million in water and wastewater utility infrastructure across four states in Q1 2025, on track to meet its 2025 capital plan [9][12] - The completion of successful general rate cases in California and Connecticut has reduced regulatory risk, with these states generating 90% of the company's water utility services net income in 2024 [11] Market Data and Key Metrics Changes - The new rates for San Jose Water effective January 1, 2025, support $450 million in capital expenditures over three years, with a total revenue increase of 9.4% [22] - In Connecticut, a $1.6 million revenue increase was authorized effective April 1, 2025, with a cumulative surcharge now at 4.9% [24][25] Company Strategy and Development Direction - The company is focused on a long-term growth strategy that includes a robust $2 billion capital plan and opportunistic acquisitions that benefit customers [12][60] - The company aims to maintain affordability while investing in infrastructure and enhancing operational efficiencies through technology advancements [31][33] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's performance for 2025, expecting to meet guidance of adjusted diluted EPS between $2.9 and $3 [14][45] - The leadership transition is progressing smoothly, with a focus on maintaining a strong culture of safety and service [35][68] Other Important Information - The company raised its credit outlook to stable, indicating a commitment to maintaining a strong credit rating [13] - The company is exploring a Water Quality and Treatment Adjustment mechanism to improve regulatory recovery processes [48][51] Q&A Session Summary Question: Can you frame where you're trending relative to guidance for the year? - Management indicated they are trending right on plan for the year and expect to meet the guidance of $2.9 to $3 [42][45] Question: What is the potential impact of the WQTA mechanism? - The WQTA is expected to streamline recovery for environmental improvements, enhancing regulatory capabilities for timely recovery [50][52] Question: Are there specific states in mind for potential acquisitions? - Management highlighted Texas as a prime area for continued acquisition activity, with additional opportunities in California, Connecticut, and Maine [58][60]